| Literature DB >> 33061739 |
Abstract
BACKGROUND: Curriculum development is a multi-processing activity that involves many academic and professional stakeholders. In order to detect the curriculum components, it is very helpful to determine the needs and expectations of the stakeholders concerning the graduate's competencies. The main objective of this work is to develop a curriculum for a master's degree in molecular diagnostics based on a survey of key stakeholders and according to the requirements of accreditation and certification, while maintaining its relevance with the rapidly advancing diverse techniques.Entities:
Keywords: cognitive skills; curriculum; molecular diagnostics; psychomotor skills; stakeholder
Year: 2020 PMID: 33061739 PMCID: PMC7525824 DOI: 10.2147/AMEP.S261628
Source DB: PubMed Journal: Adv Med Educ Pract ISSN: 1179-7258
Demographic Features of the Participants
| Variables | Frequency |
|---|---|
| Professor of molecular medicine/biology, PhD | 3 |
| Associate professor in molecular microbiology, PhD | 4 |
| Associate professor in molecular biology/medicine, PhD | 4 |
| Associate professor in forensic biology, PhD | 2 |
| Assistant professor in molecular immunology, PhD | 1 |
| Scientist at the Medical Genomic Research Department | 1 |
| Consultant, molecular hemato-oncology, MD | 2 |
| Consultant, HLA molecular laboratory, MD | 2 |
| Scientist/researcher in molecular genetic/cytogenetic, MD | 5 |
| Consultant, newborn screening/biochemical genetics/metabolic laboratory, MD | 3 |
| Consultant molecular virology, MD | 2 |
| Laboratory manager, laboratory technologist, MSc) | 5 |
| Molecular diagnostics laboratory supervisor, MSc) | 2 |
| Health care center laboratory | 20 |
| University | 14 |
| Research center | 2 |
| 1–3 years | 5 |
| 4–10 years | 14 |
| 11–20 years | 11 |
| >20 years | 6 |
| Male | 27 |
| Female | 9 |
| Total | 36 |
Currently Performed Molecular Methods (Yes) or Not (No) or Planned to Be Performed in the Next 5 Years (Planned) and the 95% Confidence Interval of the Used Methods
| Method | Yes | Planned | No | 95% CI | |
|---|---|---|---|---|---|
| DNA/RNA isolation | 86.1 | 11.1 | 2.8 | 64.7–91.5 | < 0.0001 |
| Conventional qualitative PCR | 77.8 | 16.7 | 5.6 | 52.0–83.5 | < 0.0001 |
| Quantitative PCR | 80.6 | 11.1 | 8.3 | 51.6–83.3 | < 0.0001 |
| Nested PCR | 41.7 | 0.0 | 58.3 | −6.15–37.2 | 0.1604 |
| Multiplex PCR | 75.0 | 16.7 | 8.3 | 45.7–79.2 | < 0.0001 |
| RT-PCR | 72.2 | 11.1 | 16.7 | 33.3–70.4 | < 0.0001 |
| RFLP | 50.0 | 0.0 | 50.0 | −22.0–22.0 | 1.0000 |
| MLPA | 36.1 | 8.3 | 55.6 | −13.8–29.3 | 0.4743 |
| Other amplific tech (ie, bDNA amp) | 41.7 | 8.3 | 50.0 | −14.1–29.6 | 0.4812 |
| Gel electrophoresis | 69.4 | 16.7 | 13.9 | 33.5–70.3 | < 0.0001 |
| Southern blotting | 36.1 | 11.1 | 52.8 | −6.0–37.1 | 0.1575 |
| FISH | 61.1 | 0.0 | 38.9 | −0.8–42.2 | 0.0612 |
| Sanger sequencing | 41.7 | 16.7 | 41.7 | −22.0–22.0 | 1.0000 |
| Pyrosequencing | 22.2 | 0.0 | 77.8 | 33.1–70.4 | < 0.0001 |
| Next generation sequencing | 30.6 | 25.0 | 44.4 | −8.2–34.2 | 0.2271 |
| Array (microarray, bead array) | 44.4 | 22.2 | 33.3 | −11.0–31.8 | 0.3370 |
| DHPLC | 27.8 | 8.3 | 63.9 | 13.1–54.2 | 0.0023 |
| GCMS | 33.3 | 0.0 | 66. 7 | 10.2–51.9 | 0.0050 |
| MALDI | 27.8 | 16.7 | 55.6 | 5.0–46.9 | 0.0176 |
| Primer design | 41.7 | 13.9 | 44.4 | −19.2–24.4 | 0.8137 |
| Assay development | 52.8 | 16.7 | 30.6 | −0.5–42.0 | 0.0576 |
| Assay verification/validation | 83.3 | 8.3 | 8.3 | 54.7–85.3 | < 0.0001 |
Abbreviations: RFLP, restriction fragment length polymorphism; DHPLC, denaturing high-performance liquid chromatography; MLPA, multiplex ligation-dependent probe amplification; FISH, fluorescent in situ hybridization; GCMS, gas chromatography-mass spectrometry; MALDI, matrix-assisted laser desorption ionization.
Expected Levels of the Graduate Competencies and the Score Rate Out of Four of the Various Molecular Techniques
| Method | Expert % | Familiar with Skills and Concepts % | Familiar with Concepts % | Unfamiliar % | Score Out of 4 |
|---|---|---|---|---|---|
| DNA/RNA isolation | 77.8 | 16.7 | 0.0 | 5.6 | 3.7 |
| Conventional qualitative PCR | 66.7 | 22.2 | 8.3 | 2.7 | 3.5 |
| Quantitative PCR | 61.1 | 16.7 | 13.9 | 8.3 | 3.3 |
| Nested PCR | 11.1 | 38.9 | 33.3 | 16.7 | 2.4 |
| Multiplex PCR | 52.8 | 19.4 | 22.2 | 5.6 | 3.2 |
| RT-PCR | 58.3 | 25.0 | 11.1 | 5.6 | 3.4 |
| RFLP | 8.3 | 33.3 | 33.3 | 25.0 | 2.2 |
| MLPA | 11.1 | 22.2 | 50.0 | 16.7 | 2.3 |
| Other amp tech (ie, bDNA amp) | 8.3 | 16.7 | 44.4 | 30.6 | 2.0 |
| Gel electrophoresis | 69.4 | 25.0 | 0.00 | 5.6 | 3.6 |
| Southern blotting | 25.0 | 41.7 | 16.7 | 16.7 | 2.7 |
| FISH | 22.2 | 33.3 | 25.0 | 19.4 | 2.6 |
| Sanger sequencing | 33.3 | 16.7 | 38.9 | 11.1 | 2.7 |
| Pyrosequencing | 0.0 | 33.3 | 33.3 | 33.3 | 2.0 |
| Next generation sequencing | 22.2 | 25.0 | 33.3 | 19.4 | 2.5 |
| Array (microarray, bead array) | 19.4 | 44.4 | 25.0 | 11.1 | 2.7 |
| DHPLC | 16.7 | 11.1 | 50.0 | 22.2 | 2.2 |
| GCMS | 27.8 | 16.7 | 41.7 | 13.9 | 2.6 |
| MALDI | 16.7 | 8.3 | 41.7 | 33.3 | 2.1 |
| Primer design | 25.0 | 33.3 | 33.3 | 8.3 | 2.8 |
| Assay development | 27.8 | 33.3 | 30.6 | 8.33 | 2.8 |
| Assay verification/validation | 44.4 | 22.2 | 33.3 | 0.0 | 3.1 |
Abbreviations: RFLP, restriction fragment length polymorphism; DHPLC, denaturing high-performance liquid chromatography; MLPA, multiplex ligation-dependent probe amplification; FISH, fluorescent in situ hybridization; GCMS, gas chromatography-mass spectrometry; MALDI, matrix-assisted laser desorption ionization.
Level of Expertise the Expected Graduates of the Program Should Have
| Level | B. Sc | M. Sc | 95% CI | |
|---|---|---|---|---|
| DNA/RNA isolation | 77. 8 | 22.2 | 33.1–70.4 | < 0.0001 |
| Qualitative PCR | 80.6 | 19.4 | 39.1–74.8 | < 0.0001 |
| Quantitative PCR | 58.3 | 41.7 | −6.2–37.2 | 0.1604 |
| Nested PCR | 50.0 | 50.0 | −22.0–22,0 | 1.0000 |
| Multiplex PCR | 38.9 | 61.1 | −0.8–42.2 | 0.0612 |
| RT-PCR | 63.9 | 36.1 | 4.7–47.1 | 0.0192 |
| RFLP | 41.7 | 58.3 | −6.2–37.2 | 0.1604 |
| (MLPA) | 27.8 | 72.2 | 21.5–61.3 | 0.0002 |
| Other amplification techniques (ie, bDNA amp) | 38.9 | 61.1 | −0.8–42.2 | 0.0612 |
| Gel electrophoresis | 75.0 | 25.0 | 27.3–66.0 | < 0.0001 |
| Southern blotting | 61.1 | 38.9 | −0.8–42.2 | 0.0612 |
| FISH | 69.4 | 30.6 | 15.8–56.6 | 0.0011 |
| Sanger sequencing | 36.1 | 63.9 | 4.7–47.1 | 0.0192 |
| Pyrosequencing | 50.0 | 50.0 | −22.0–22,0 | 1.0000 |
| Next generation sequencing | 25.0 | 75.0 | 27.3–65.9 | < 0.0001 |
| Array (microarray, bead array) | 33.3 | 66.7 | 10.2–51.9 | 0.0050 |
| DHPLC | 30.6 | 69.4 | 15.8–56.6 | 0.0011 |
| GCMS | 25.0 | 75.0 | 27.3–65.9 | < 0.0001 |
| MALDI | 22.2 | 77.8 | 33.1–70.4 | < 0.0001 |
| Primer design | 47.2 | 52.8 | −16.7–27.1 | 0.6394 |
| Assay development | 27.8 | 72.2 | 21.5–61.3 | 0.0002 |
| Assay verification/validation | 36.1 | 63.9 | 4.7–47.1 | 0.0192 |
| Average | 46.2 | 53.8 | −14.8–29.0 | 0.5230 |
Notes: Two-sample t-test between percent. N - 1ʹ chi-squared test.
Abbreviations: RFLP, restriction fragment length polymorphism; DHPLC, denaturing high-performance liquid chromatography; MLPA, multiplex ligation-dependent probe amplification; FISH, fluorescent in situ hybridization; GCMS, gas chromatography-mass spectrometry; MALDI, matrix-assisted laser desorption ionization.
Rate the Following Issues of Clinical Quality Control and Management in Terms of How Expert Recent Graduates of a Master’s Degree Program in Molecular Diagnostics Should Be
| Expert | Familiar with Skills and Concepts | Familiar with Concepts | Unfamiliar | Score | |
|---|---|---|---|---|---|
| Quality assurance | 41.7 | 58.3 | 0 | 0 | 3.4 |
| Proficiency testing | 50.0 | 50.00 | 0 | 0 | 4.0 |
| Regulatory/accreditation requirements | 30.6 | 69.4 | 0 | 0 | 3.3 |
| Assay validation | 69.4 | 30.6 | 0 | 0 | 3.7 |
| Laboratory safety | 94.4 | 5.6 | 0 | 0 | 3.9 |
Program Chart of Didactic and Practical Training
| Phase | Didactic and Practical | Credits |
|---|---|---|
| Semester 1 | Biochemistry of Nucleic Acids and Proteins Molecular Genetics Basic Molecular Biology Research Methods and Biostatistics and Bioinformatics | 15 |
| Semester 2 | Molecular Diagnostics I: Microorganisms Molecular Diagnostics II: The Molecular Basis of Inherited Diseases and neonatal screening Molecular Diagnostics III: Molecular Oncology and Hematology Molecular Diagnostics IV: Human Identification, DNA-based tissue typing, and pharmacogenomics Quality Assurance in Molecular Diagnostics Molecular Laboratory | 16 |
| Semester 3 and 4 | Research Project in Molecular Diagnostics | 8 |
| Total | 39 |